TapImmune Inc. is Pleased to Provide an Update on Corporate Events and Milestones for 2014
Business Wire - Thu Apr 03, 10:03AM CDT
TapImmune Inc. (OTCQB:TPIV), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease is pleased to update shareholders and investors on the most recent corporate events and milestones for the year ahead. Glynn Wilson TapImmune's CEO provided insights in an interview on the floor of the NASDAQ recently which can be seen by navigating to the following link:
TapImmune Inc. is Pleased to Announce the Filing of New Intellectual Property Surrounding its Novel and Proprietary Platform Expression System PolyStart(TM)
Business Wire - Thu Mar 20, 7:47AM CDT
TapImmune Inc. (OTCQB: TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has filed a new patent application for a novel technology platform designed to enhance the visibility of cancer or infected cells to a patient's immune system, a critical aspect of an effective vaccine.
TapImmune Inc. is Pleased to Announce the Signing of an Exclusive Option Agreement for a New Phase 1 Clinical Program in Breast and Ovarian Cancer
Business Wire - Wed Mar 19, 7:45AM CDT
TapImmune Inc. (OTCQB: TPIVD), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has signed an exclusive option agreement for a set of unique peptide epitopes targeting Folate Receptor Alpha in both breast cancer and ovarian cancer.
TapImmune Inc. To Present at 2014 Annual Roth Capital Growth Stock Conference
ACCESSWIRE - Wed Mar 05, 7:31AM CST
Seattle, WA / ACCESSWIRE / March 5, 2014 / TapImmune Inc. (OTCQB: TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, will be presenting at the Annual Roth Capital Growth Stock Conference on March 12 2014.
TapImmune Releases Positive Interim Data on Phase I Clinical Trial in HER2/neu+ Breast Cancer
Business Wire - Mon Mar 03, 7:00AM CST
TapImmune Inc. (OTCQB:TPIVD) is pleased to report that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients have raised specific T-cell immune responses against a set of naturally processed HER2/neu Class II antigenic epitopes. The Phase I trial is being carried at the Mayo Clinic, Rochester, MN.
TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress
Business Wire - Thu Feb 27, 8:38AM CST
TapImmune Inc. (OTCQB:TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders.